Valneva SE
http://www.valneva.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Valneva SE
Asia Deal Watch: ProGen To Partner With Rani On GLP-2 Agonist In Obesity
Plus deals involving Healios/Astellas Institute for Regenerative Medicine, Otsuka/Ionis, IMBiologics/Navigator and more.
Valneva Cements Lead In Chikungunya Space With EU Nod
The green light from the European Commission for Ixchiq marks the third regulatory approval for the world’s first vaccine for chikungunya and extends the French biotech's lead over rival Bavarian Nordic.
Chikungunya Vaccine, Hemophilia B Gene Therapy Among 14 Products On Track For EU Approval
The EU is on track to get its first vaccine for preventing the disease caused by chikungunya virus. Thirteen other products have also been recommended for pan-EU approval.
EU Crunch Time For Myriad Drugs Marks A Busy May Meeting For CHMP
The latest meeting of the European Medicines Agency’s human medicines committee, the CHMP, is taking place this week. Decisions are expected for 13 drug marketing applications, there will be a number of oral explanation meetings, and activity is expected relating to a drug at the center of a case involving the European Commission’s rejection of an EMA recommendation.
Company Information
- Industry
- Contract Research, Toxicology Testing-CRO
-
Pharmaceuticals
- Drug Delivery
- Vaccines
-
Biotechnology
- Drug Discovery Tools
- Synthesis Technologies, Production Processes
- Transgenics
-
Large Molecule
- Antibodies
- Other Names / Subsidiaries
-
- BliNK Biomedical SAS
- Crucell Sweden AB
- Iomai Corporation
- Intercell USA, Inc.
- Intercell AG, Vivalis
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice